SCHEMBL8364732

SCHEMBL8364732

O=C(NO)c1ccccc1S(=O)(=O)N1CCC2(CCCCC2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 10/20 0.59
MMP13 P45452 10/20 0.59
CYP3A4 P08684 3/20 0.45
CYP2C19 P33261 3/20 0.45
TSHR P16473 3/20 0.45
CYP2C9 P11712 2/20 0.45
ACLY P53396 1/20 0.45
USP2 O75604 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 2/20 0.43
MMP9 P14780 2/20 0.42
MMP8 P22894 2/20 0.42
MMP12 P39900 2/20 0.42
MMP14 P50281 2/20 0.42
MMP16 P51512 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MMP1 P03956 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12150842 0.76 MMP2 (0.69) MMP2MMP13HDAC3HDAC1HDAC2
SCHEMBL5898957 0.74 MMP2 (1.00) MMP2MMP13USP2ALDH1A1
SCHEMBL5898933 0.74 MMP2 (1.00) MMP2MMP13HDAC6MMP3
SCHEMBL7076468 0.73 KMT2A (0.59) MMP2MMP13TSHRHDAC6ALDH1A1
SCHEMBL5899024 0.72 MMP2 (1.00) MMP2MMP13TSHRALDH1A1
SCHEMBL7073728 0.72 MMP2 (0.60) MMP2MMP13TSHRACLYHDAC3
SCHEMBL7076239 0.72 MMP2 (0.60) MMP2MMP13ACLYHDAC3HDAC1
SCHEMBL8364765 0.72 MMP2 (0.69) MMP2MMP13MMP9MMP8MMP12
SCHEMBL7079810 0.72 ALDH1A1 (0.59) MMP2MMP13TSHRUSP2HDAC3
SCHEMBL5898966 0.69 CHRM1 (0.60) MMP2MMP13ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003007954-A2 SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2003-01-30 WO disclosed